Summary: Kampo is a traditional Japanese herbal medicine and widely used in clinical practice in Japan. Little is known about interactions between Kampo and other medicines. Kampo contains many aglycones, which can be conjugated by UDP-glucuronosyltransferase (UGT). Therefore, in the present study, the effects of Kampo on human UGT1A1 activity were investigated in vitro. Substrates of human UGT1A1, b-estradiol or 7-ethyl-10-hydroxycamptothecin (SN-38), were incubated with human liver microsomes in the presence of 51 Kampos, 14 medicinal herbs and their components. b-Estradiol 3-glucuronidation was strongly inhibited by some Kampos such as Bofu-tsusho-san, Mashinin-gan and Otsuji-to. Medicinal herbs such as Daio ( Rhei Rhizoma), Kanzo (Glycyrrhizae Radix), Keihi (Cinnamomi Cortex) and Ogon (Scutellariae Radix) exhibited potent inhibition on that activity. On b-estradiol 3-glucuronidation, the major component of Keihi (cinnamaldehyde) and Ogon (wogonin) exhibited mixed-type inhibition of Ki with values of 0.7 mM and 2.8 mM, respectively. On SN-38 glucuronidation, the inhibitory potencies of Kampos, medicinal herbs and their components tended to be similar to those on b-estradiol 3-glucuronidation. In the present study, Kampo was clarified to inhibit b-estradiol and SN-38 glucuronidation mainly catalyzed by UGT1A1.
Introduction
Kampo is a mixture of several medicinal herbs and widely used in clinical practice in Japan. Kampo is a traditional medicine of Chinese origin and was uniquely developed in Japan. Many components in Kampo may have pharmacological effects that could lead to improvement of disease and the maintenance of homeostasis. Since scientific research on its efficacy has advanced, prescriptions of Kampo have been increasing. Recently, clinical trials on Kampo have been performed in the US. However, many components of the herbs in Kampo resulted in complex pharmacological and toxicological effects. [1] [2] [3] [4] Several adverse reactions caused by Kampo have been reported. 5) Warnings concerning Sho-saiko-to and interstitial pneumonia were given by the Japanese Ministry of Health, Labour, and Welfare. Especially, when co-administered with interferons a/b, Sho-saiko-to was suggested to induce interstitial pneumonia. One of the most famous medicinal herbs, Kanzo (Glycyrrhizae Radix), represents more than 70% of the prescribed Kampo. A high intake of glycyrrhizic acid, a major component of Kanzo, causes hypermineralocorticoidism. 6) Irinotecan hydrochloride-induced intestinal toxicity is prevented by co-administration of a Kampo, Hange-shasin-to, 7) which is therefore used in clinical practice in Japan. Since several Kampos and medicinal herbs can be obtained over the counter, it is possible that co-administration with prescribed medicines often occurs. Kampo is often prescribed in individuals suffering from chronic disease and therefore may be frequently co-administered with other medicines. However, information on interactions between Kampo and medicines is limited. Interactions with herbs via cytochrome P450 (P450) have been reported and have received attention. 8) Interactions of St. John's wort or grapefruit juice via P450 are well known. Inhibitory effects of Kampo on P450 activity have been reported, 9) but interactions of Kampo via other drug metabolizing enzymes have not been examined. The present study investigates the effects of Kampo on UDPglucuronosyltransferase (UGT), one of the most important phase II enzymes.
Although a few components have been quantified in herbs, the contents of many components have not been clarified. It is known that there are many aglycones and glycosides including glucuronide in medicinal herbs. Glycosides can be absorbed after hydrolysis to the corresponding aglycone. 10) It is possible that aglycones including saponin and phenolic compounds can be conjugated by UGT, leading to drug interactions.
In the present study, to clarify interactions between Kampo and others medicines, the inhibitory effect of Kampo on human UGT activity was investigated in vitro. UGT1A1 is responsible for metabolism of many endogenous and xenobiotic compounds. Drug interactions via UGT1A1 have been reported. Interindividual differences in the toxicity of SN-38 are caused by UGT1A1 polymorphism.
11)
The inhibition of UGT1A1 may be one reason for unconjugated hyperbilirubinemia. 12, 13) Therefore, we first focused on the inhibitory effects of Kampo on UGT1A1 activity. The substrates of human UGT1A1, b-estradiol or 7-ethyl-10-hydroxycamptothecin (SN-38), were incubated with human liver microsomes in the presence of 51 Kampos, 14 medicinal herbs and their components.
Materials and methods

Chemicals:
The extracts of Kampo (a mixture of several medicinal herbs) and medicinal herbs clinically used in Japan were kindly supplied by Tsumura & Co. (Tokyo, Japan). According to the method previously described, 14) Kampo and medicinal herbs were extracted with purified water. We chose 51 Kampos prescribed frequently in Japan, 14 medicinal herbs and 11 components. The fifty one Kampos were as follows: Bakumondo-to, Bofu-tsusho-san, Boi-ogi-to, Byakko-ka-ninjin-to, Choreito, Cho-to-san, Dai-kenchu-to, Gorei-san, Gosha-jinkigan, Goshuyu-to, Hachimi-jio-gan, Hange-byakujutsutemma-to, Hange-koboku-to, Hange-shashin-to, Hochuekki-to, Jumi-haidoku-to, Juncho-to, Juzen-taiho-to, Kakkon-to, Kami-kihi-to, Kami-shoyo-san, Keigai-rengyo-to, Keishi-bukuryo-gan, Keishi-bukuryo-gan-ka-yokuinin, Keishi-ka-jutsu-bu-to, Keishi-ka-shakuyaku-daio-to, Kikyoto, Mao-bushi-saishin-to, Mashinin-gan, Ninjin-yoei-to, Oren-gedoku-to, Otsuji-to, Rikkunshi-to, Ryo-kei-jutsukan-to, Saiko-ka-ryukotsu-borei-to, Saiko-keishi-kankyoto, Sairei-to, Seihai-to, Seijo-bofu-to, Shakuyaku-kanzo-to, Shimbu-to, Sho-kenchu-to, Sho-saiko-to, Sho-seiryu-to, Sokei-kakketsu-to, Tokaku-joki-to, Toki-shakuyaku-san, Toki-shigyaku-ka-goshuyu-syokyo-to, Unkei-to, Unsei-in and Yoku-kan-san. The fourteen medicinal herbs were as follows: Bukuryo (Hoelen), Daio (Rhei Rhizoma), Hange (Pinelliae Tuber), Kanzo (Glycyrrhizae Radix), Keihi (Cinnamomi Cortex), Kikyo (Platycodi Radix), Ninjin (Gins eng Radix), Ogon (Scutellariae Radix), Saiko (Bupleuri Radix), Shakuyaku (Paeoniaceas Radix), Shokyo (Zingiberis Rhizoma), Sojutsu (Atractylodis lanceae Rhizoma), Taiso (Zizyphi Fructus) and Toki (Angelicae Radix). The eleven components were as follows: the major components of Daio: emodin, rhein, sennidine A, and sennoside A; the major components of Kanzo: glycyrrhetinic acid and glycyrrhizic acid; the major components of Keihi: cinnamaldehyde and cinnamic acid; the major components of Ogon: baicalein, baicalin, and wogonin. Baicalein, baicalin, cinnamaldehyde, cinnamic acid, glycyrrhetinic acid, glycyrrhizic acid, sennoside A, and wogonin were obtained from Wako Pure Chemicals (Osaka, Japan). Emodin and rhein were purchased from Sigma-Aldrich (St. Louis, MO, USA). Sennidine A was obtained from ChromaDex (Santa Ana, CA, USA). UDP-glucuronic acid (UDP-GA), alamethicin, b-estradiol, and b-estradiol 3-glucuronide were purchased from Sigma-Aldrich. SN-38 was purchased from Toronto Research Chemicals (North York, Canada). SN-38 glucuronide was kindly provided by Yakult Honsha (Tokyo, Japan). Pooled human liver microsomes and pooled human jejunum microsomes were purchased from BD Gentest (Woburn, MA, USA) and KAC (Kyoto, Japan), respectively. All other chemicals and solvents were of analytical or the highest grade commercially available.
Inhibition analyses of b-estradiol 3-glucuronidation: A typical incubation mixture (total volume, 0.2 mL) contained 20 mM b-estradiol, 50 mM Tris-HCl buffer (pH 7.4), 10 mM MgCl2, 120 mg of alamethicin/ mg microsomal protein, 2 mM UDP-GA, 0.2 mg/mL human liver microsomes or human jejunum microsomes, and Kampo, medicinal herb or component. In the preliminary study, the rate of this activity was linear with respect to the microsomal protein concentration and incubation time under the present experimental conditions. b-Estradiol and alamethicin were dissolved with dimethyl sulfoxide and 30% methanol, respectively. The Kampo and medicinal herbs were dissolved with distilled water. All components except glycyrrhizic acid (distilled water) were dissolved with dimethyl sulfoxide. The final concentration of the organic solvent in the reaction mixture was º1% (v/v) for the Kampo and herbal medicine and º2% (v/v) for the components. In the preliminary study, organic solvent concentration did not affect enzyme activity up to 2% (v/v). The reaction mixture was incubated for 10 min at 379 C. The concentration of Kampo was 1 mg/mL. The concentrations of medicinal herbs were as follows: Shokyo, 0.1 mg/mL; Hange and Toki, 0.5 mg/mL; Bukuryo, Daio, Kanzo, Keihi, Kikyo, Ninjin, Ougon, Saiko, Shakuyaku, Sojutsu, and Taiso, 1.0 mg/mL. The concentrations of components in liver microsomes were 50 and 100 mM except for cinnamalde-hyde (10 mM) and those in jejunum microsomes were 1 mM except for cinnamaldehyde (10 mM) and rhein (250 mM). The concentrations of cinnamaldehyde and rhein were maxima in the present experimental conditions. After removal of protein by centrifugation at 1,000 g for 10 min, a portion of the sample was subjected to highperformance liquid chromatography with a Develosil C30-UG 5-mm analytical column (4.6×150 mm, Nomura Chemical, Aichi, Japan) or TSK-GEL 80Ts 5-mm analytical column (4.6×250 mm, Tosoh, Tokyo, Japan). Product formation was measured as described previously 15) with slight modification. The mobile phase was 30% acetonitrile in 1 mM perchrolic acid or 20% acetonitrile in 10 mM ammonium acetate. The analytical column and mobile phase were altered when the peak derived from the Kampo or medicinal herb overlapped with that of bestradiol 3-glucuronide. For determination of the Ki in human liver microsomes, the concentration of b-estradiol ranged from 5 to 40 mM and those of the inhibitors ranged as follows: Kampo: Bofu-tsusho-san, 100-200 mg/mL; Mashinin-gan, 30-90 mg/mL; Otsuji-to, 50-200 mg/mL. Medicinal herb: Daio, 10-30 mg/mL; Kanzo, Keihi, and Ogon, 30-90 mg/mL. Component: baicalein, 10-30 mM; cinnamaldehyde, 0.5-2 mM; emodin, 10-40 mM; glycyrrhetinic acid, 20-80 mM; sennidine A, 10-30 mM; wogonin, 5-20 mM.
The Ki values were estimated from the fitted curve using a computer program (K cat; BioMetallics, Princeton, NJ) designed for nonlinear regression analysis.
Inhibition analyses of SN-38 glucuronidation: A typical incubation mixture (total volume, 0.1 mL) contained 40 mM SN-38, 50 mM Tris-HCl buffer (pH 7.4), 5 mM MgCl2, 100 mg of alamethicin/mg microsomal protein, 3 mM UDP-GA, 0.25 mg/mL human liver microsomes or human jejunum microsomes and the Kampo, medicinal herbs or their components. In the preliminary study, the rate of this activity was linear with respect to microsomal protein concentration and incubation time under the present experimental conditions. SN-38 and alamethicin was dissolved in 50% dimethyl sulfoxide and 30% methanol, respectively. The Kampo and medicinal herbs were dissolved with distilled water. All components except glycyrrhizic acid (distilled water) were dissolved with dimethyl sulfoxide. The final concentration of organic solvent in the reaction mixture was º1% (v/v) for the Kampo and herbal medicine and º2% (v/v) for the components. In the preliminary study, the organic solvent concentration did not affect enzyme activity up to 2% (v/v). The concentrations of the Kampo, medicinal herb and components were described under inhibition analyses of b-estradiol 3-glucuronidation. The reaction mixture was incubated for 45 min at 379 C. After removal of protein by centrifugation at 1,000 g for 10 min, a portion of the sample was subjected to high-performance liquid chromatography with a TSK-GEL 80Ts 5-mm analytical column (4.6×150 mm). Product formation was measured as described previously 16) with slight modification. The mobile phase was acetonitrile: methanol: 3 mM sodium 1-octanesulfonate (pH 2.5)＝ 22:6:72 and the flow rate was 1.0 mL/min. The eluent was monitored fluorometrically (excitation, 370 nm; emission, 425 nm). For determination of Ki in human liver microsomes, the concentration of SN-38 ranged from 10 to 80 mM and the inhibitors ranged as follow: Kampo: Bofu-tsusho-san, 50-200 mg/mL; Hange-shashinto, 40-250 mg/mL; Mashinin-gan, 50-200 mg/mL; Orengedoku-to, 100-400 mg/mL; Otsuji-to, 120-400 mg/mL; Tokaku-joki-to, 40-200 mg/mL. Medicinal herb: Daio, 20-60 mg/mL; Kanzo, 40-160 mg/mL; Ogon, 30- 
Results
Inhibitory effects of Kampo on b-estradiol 3-glucuronidation in human liver microsomes: The inhibitory effects of 51 Kampos, 14 medicinal herbs, and their components on b-estradiol 3-glucuronidation in human liver microsomes were determined. As shown in Figure 1 , b-estradiol 3-glucuronidation in human liver microsomes was strongly inhibited (À90% inhibition) by 12 Kampos, (Bofu-tsusho-san, Juncho-to, Kakkon-to, Keigai-rengyo-to, Keishi-ka-shakuyaku-daio-to, Mashiningan, Otsuji-to, Ryo-kei-jutsu-kan-to, Saiko-keishi-kankyoto, Seijo-bofu-to, Shakuyaku-kanzo-to, and Tokaku-jokito). All Kampos except Chorei-to exhibited more than 50% inhibition on this activity. As shown in Figure 2A , the activity was strongly inhibited by 4 medicinal herbs, Daio, Kanzo, Keihi, and Ogon. The major components of Daio (emodin and sennidine A), Keihi (cinnamaldehyde) and Ogon (baicalein and wogonin) inhibited the b-estradiol 3-glucuronidation (Fig. 2B) . The inhibitory potencies of aglycones (glycyrrhetinic acid and baicalein) were much stronger than those of glycosides (glycyrrhizic acid and baicalin).
Inhibition constants for b-estradiol 3-glucuronidation in human liver microsomes: Ki of the Kampos, medicinal herbs and their components are shown in Table 1 and Figure 3 . The inhibition pattern of Bofutsusho-san was competitive but 2 other Kampos exhibited mixed-type inhibition. The medicinal herbs exhibited similar or lower apparent Ki compared with Kampos. In the case of the components, apparent Ki of cinnamaldehyde, emodin, glycyrrhetinic acid, sennidine A, and wogonin were 0.7, 8.8, 28.8, 23.4 and 2.8 mM, respectively.
Inhibitory effects of Kampo on b-estradiol 3-glucuronidation in human jejunum microsomes: The concentration of b-estradiol was 20 mM. The concentrations of the medicinal herbs were as follows: 0.1 mg/mL, Shokyo; 0.5 mg/mL, Hange and Toki; 1.0 mg/mL, Bukuryo, Daio, Kanzo, Keihi, Kikyo, Ninjin, Ogon, Saiko, Shakuyaku, Sojutsu and Taiso. The concentrations of the components were 50 and 100 mM except for cinnamaldehyde (10 mM). Glycyrrhetinic acid and baicalein were aglycones of glycyrrhizic acid and baicalin, respectively. Each data point represents the mean of duplicate determinations. Differences in the two values were less than 2.5% from the mean. Control activity was 1.5 nmol/min/mg protein. ND, not detected. Inhibition of UGT1A1 Activity by Kampo
The medicinal herbs and their components, which exhibited strong inhibition on b-estradiol 3-glucuronidation in human liver microsomes, were also investigated for their inhibitory potencies in human jejunum microsomes (Fig. 4) . The inhibitory effects of medicinal herbs and their components in human jejunum microsomes tended to be similar to those in liver microsomes. However, sennoside A and wogonin exhibited strong inhibition only in human jejunum and liver microsomes, respectively.
Inhibitory effects of Kampo on SN-38 glucuronidation in human liver microsomes: The inhibitory effects of 51 Kampos, 14 medicinal herbs and their components on SN-38 glucuronidation in human liver microsomes were determined. As shown in Figure 5 , SN-38 glucuronidation in human liver microsomes was strongly inhibited by 7 Kampos (Bofu-tsusho-san, Mashinin-gan, Oren-gedoku-to, Otsuji-to, Saiko-keishikankyo-to, Shakuyaku-kanzo-to, and Tokaku-joki-to). As shown in Figure 6A , the activity was strongly inhibited by 4 medicinal herbs, Daio, Kanzo, Keihi, and Ogon. These 4 medicinal herbs exhibited strong inhibition on both SN-38 and b-estradiol glucuronidation. The major components of Daio (emodin and sennidine A), Kanzo (glycyrrhetinic acid), Keihi (cinnamaldehyde), and Ogon (baicalein, baicalin, and wogonin) inhibited the SN-38 glucuronidation (Fig. 6B) .
Inhibition constants for SN-38 glucuronidation in human liver microsomes: Apparent Ki of the Kampos, medicinal herbs and their components are shown in Table 2 and Figure 7 . The Kampos and medicinal herbs except Hange-shasin-to exhibited mixedtype inhibition. Cinnamaldehyde, a major component of Keihi, was the most potent inhibitor among all the com- ponents examined. Apparent Ki of the Kampos, medicinal herbs and their components on SN-38 glucuronidation were slightly higher than those on the b-estradiol 3-glucuronidation.
Inhibitory effects of Kampo on SN-38 glucuronidation in human jejunum microsomes: The medicinal herbs and their components, which exhibited strong inhibition on SN-38 glucuronidation in human liver microsomes, were also investigated for their inhibitory potencies in human jejunum microsomes (Fig. 8) .
The inhibitory effects of the medicinal herbs and their components in human jejunum microsomes were similar to those in liver microsomes.
Discussion
UGT1A1 is expressed mainly in liver and intestine in humans 17) and plays an important role in the glucuronidation of b-estradiol and SN-38. 18) In the present study, many Kampos exhibited strong inhibition toward b-estradiol and SN-38 glucuronidation. Kampos with low Ki for b-estradiol 3-glucuronidation also strongly inhibited SN-38 glucuronidation. The inhibitory potencies on b-estradiol 3-glucuronidation were well correlated with those on SN-38 glucuronidation (r＝0.87) in the 51 Kampos. In the Kampos that exhibited more than 80% inhibition of both b-estradiol and SN-38 glucuronidation, Kanzo, Kei- hi, Ogon and Daio were contained at high frequency. However, the inhibitory potencies of the Kampos did not depend on the content of these medicinal herbs, indicating that the Kampos showed complicated inhibition on these activities. Although many components in the Kampos and medicinal herbs may be involved in the inhibition of these activities, this cannot explain why competitive type inhibition occurred. SN-38 was mainly glucuronized by UGT1A1 in human liver but also by UGT1A6 and UGT1A9. 19) b-estradiol was glucuronized mainly by UGT1A1 and slightly by UGT1A3. 20) These activities were mainly catalyzed by UGT1A1 in liver, and therefore it is suggested that Kampos and medicinal herbs inhibit UGT1A1 activity.
In the present study, representative components of medicinal herbs were examined. The contents of major components in Kampo or medicinal herbs are highly variable according to the lot. Japanese Pharmacopoeia determined that Kanzo and Ogon contain more than 2.5% glycyrrhizic acid and 10.0% baicalin, respectively. The content of glycyrrhizic acid in Kanzo ranged from 0.60% to 7.0%. 21) The relative content of cinnamaldehyde was 48.4-62.1% in Keihi. 22) The content seems to vary depending on the herb. Lot-to-lot differences in Kampo may affect inhibitory effects on UGT activity. Many aglycones and glycosides are known as components of medicinal herbs. The major components of Kanzo were glycyrrhetinic acid (aglycone) and glycyrrhizic acid (glycoside) 23) and those of Ogon were baicalein (aglycone) and baicalin (glycoside). 24) As shown in Figures 2B and 6B , aglycones exhibited stronger inhibition than glycosides. Yokoi et al. 25) reported that SN-38 glucuronidation in human liver microsomes was inhibited by aglycones found in herbs, which is consistent with our results. Baicalein, a substrate for UGT1A1, UGT1A8, and UGT1A9 in humans, 26) exhibited mixed-type inhibition on SN-38 glucuronidation. Thus, aglycone in medicinal herbs may also be glucuronized by UGT, leading to inhibition of UGT activity. The major components of Daio, sennoside A and sennoside B, 27) are well-known purgatives. One major metabolite of sennoside A is sennidine. 28) Thus, in the case of sennoside, the metabolite exhibited stronger inhibition than the parent compound.
The inhibitory patterns of some components were different between b-estradiol and SN-38 glucuronidation. Rios and Tephly 29) suggest that UGT1A1 has several binding sites. The substrates (SN-38 and b-estradiol) and/or the components may have different affinities toward each binding site. Sennoside A exhibited strong inhibition in jejunum microsomes but not liver microsomes. b-Estradiol 3-and SN-38 glucuronidation is mainly catalyzed by UGT1A1, but several UGT isoforms are also involved in these activities. One reason for this may be that UGT isoforms expressed in these tissues are different. However, further study is needed to clarify this point.
Concerning many Kampos, it remains unclear how components are absorbed and what their concentrations are in plasma in humans, which makes it difficult to estimate drug interactions. According to a report by Foti et al., 30) the estimated gut concentration of herbal mixture was as follows: a single tablet of herbal mixture (g) was divided by intestinal volume (¿500 mL). The dose of Kampo is usually 1.0-1.5 g three times daily in the form of Kampo extracts. Therefore, Kampo concentration in the gut is approximately 2.0-3.0 g/mL. However, the accurate concentration in intestine has not been clarified nor that in liver. The plasma concentration profiles of baicalin have been reported after oral administrations of Sho-saiko-to to humans. 31) In this report, the maximum plasma concentration of baicalin was approximately 55 ng/mL (0.1 mM). Muto et al. 31) suggest that the detected baicalin in plasma may result from glucuronidation of baicalein absorbed into the body. Although baicalein concentration in the liver and intestine may be higher than that in plasma, it is very difficult to compare liver and intestinal concentrations and Ki in humans due to lack of information. The pharmacokinetics of the major components of Kampo need to be clarified.
Takahashi et al. 9) reported that phase I drug metabolizing enzymes such as CYP3A4 and CYP1A2 were inhibited by Hochu-ekki-to, Sairei-to and Syo-saiko-to in human liver microsomes. The major metabolic pathways of b-estradiol in humans are 2-hydroxylation by CYP3A4 and CYP1A2 32) and glucuronidation by UGT1A1. 33) In the present study, Sairei-to inhibited b-estradiol 3-glucuronidation suggesting that the plasma concentration of b-estradiol in humans may be elevated by inhibition of phase I and II enzymes. Estrogen drugs are prescribed for menopausal syndrome and menoxenia. As described in a datasheet from Tsumura & Co., Kami-syo-san, Keishibukuryo-gan, Keishi-bukuryo-gan-ka-yokuinin, Tokakujoki-to, Toki-shakuyaku-san, Unkei-to and Unsei-in are prescribed for menopausal syndrome and menoxenia in clinical practice. If b-estradiol is co-administered with Tokaku-joki-to, b-estradiol 3-glucuronidation may be inhibited, leading to elevation of estradiol concentration.
Bilirubin is a specific substrate for UGT1A1. Some flavonoids inhibit bilirubin glucuronidation. 34) Since the present study clarifies the inhibition of UGT1A1 by Kampo, we should be careful about increase in bilirubin level in vivo in humans after treatment with Kampo. Further study on extrapolation from in vitro to in vivo is needed.
In conclusion, the present study clarifies that Kampo inhibits UGT1A1 activity. The components of Kampo, medicinal herbs and their component also demonstrated inhibition. The pharmacological and toxicological effects of Kampo have been studied recently, although the pharmacokinetics of Kampo, especially the components, are still unknown. Therefore, since it is extremely difficult to extrapolate inhibitory effect in vitro to in vivo, we may keep the possibility of drug interactions by Kampo via UGT1A1 in mind.
